Page last updated: 2024-10-30

memantine and Drug Withdrawal Symptoms

memantine has been researched along with Drug Withdrawal Symptoms in 24 studies

Research Excerpts

ExcerptRelevanceReference
"Chronic amphetamine use results in anxiety-like states after drug cessation."7.79The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. ( Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH, 2013)
"Although memantine is widely used and generally considered safe, an abrupt cessation of memantine may result in discontinuation syndrome that can be distressing and result in decline of natural course."7.75Two cases of discontinuation syndrome following cessation of memantine. ( Han, IW; Koo, MS; Kwak, YT; Suk, SH, 2009)
"The present study aimed to evaluate the effects of low-affinity NMDA receptor channel blockers (memantine and MRZ 2/579) on aggression facilitated by morphine withdrawal in mice."7.70Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. ( Bespalov, AY; Sukhotina, IA, 2000)
"The current experiments explore aggression and medial prefrontal cortex (mPFC) glutamate as consequences of withdrawal from intermittent access to EtOH and changes in aggression and mPFC glutamate caused by NMDAR antagonists memantine and ketamine."3.81Aggression and increased glutamate in the mPFC during withdrawal from intermittent alcohol in outbred mice. ( DeBold, JF; Holly, EN; Hwa, LS; Miczek, KA; Nathanson, AJ; Newman, EL; Shimamoto, A; Tayeh, JK; Wilens, AR, 2015)
"Chronic amphetamine use results in anxiety-like states after drug cessation."3.79The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. ( Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH, 2013)
"Although memantine is widely used and generally considered safe, an abrupt cessation of memantine may result in discontinuation syndrome that can be distressing and result in decline of natural course."3.75Two cases of discontinuation syndrome following cessation of memantine. ( Han, IW; Koo, MS; Kwak, YT; Suk, SH, 2009)
"The present study aimed to evaluate the effects of low-affinity NMDA receptor channel blockers (memantine and MRZ 2/579) on aggression facilitated by morphine withdrawal in mice."3.70Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. ( Bespalov, AY; Sukhotina, IA, 2000)
"Demand for treatments for severe opioid use disorder is increasing worldwide."2.66Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review. ( Fluyau, D; Pierre, CG; Revadigar, N, 2020)
"Memantine was well tolerated with similar rates of adverse effects between treatment groups."2.61Adjunctive memantine for opioid use disorder treatment: A systematic review. ( Brown, JN; Elias, AM; Pepin, MJ, 2019)
"Catatonia is a severe motor syndrome found in approximately 10% of all acute psychiatric hospital admissions."1.43Catatonia and cannabis withdrawal: A case report. ( Amad, A; Caudron, M; Deheul, S; Geoffroy, PA; Rolland, B; Thomas, P, 2016)
"Trichostatin A was also observed to exert a synergistic interaction with Ac-DEVD-CHO."1.38Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome. ( Rachamalla, M; Rehni, AK; Singh, N; Tikoo, K, 2012)
"Memantine was neuroprotective when administered during ethanol withdrawal."1.37Administration of memantine during ethanol withdrawal in neonatal rats: effects on long-term ethanol-induced motor incoordination and cerebellar Purkinje cell loss. ( Idrus, NM; McGough, NN; Riley, EP; Thomas, JD, 2011)
"morphine was co-administered with memantine or MK-801."1.32Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal. ( Aguilar, MA; Cauli, O; Maldonado, C; Miñarro, J; Rodríguez-Arias, M, 2003)
"Treatment with memantine resulted in a complete reversal of these behavioral impairments."1.31Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. ( Lukoyanov, NV; Paula-Barbosa, MM, 2001)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (4.17)18.2507
2000's11 (45.83)29.6817
2010's11 (45.83)24.3611
2020's1 (4.17)2.80

Authors

AuthorsStudies
Elias, AM1
Pepin, MJ1
Brown, JN1
Fluyau, D1
Revadigar, N1
Pierre, CG1
Romero-Gonzalez, M1
Shahanaghi, A1
DiGirolamo, GJ1
Gonzalez, G1
Yuanyuan, J1
Junyan, Z1
Cuola, D1
Jingjing, C1
Yuhui, S1
Dan, X1
Wei, D1
Yongsheng, Z1
Koltunowska, D1
Gibula-Bruzda, E2
Kotlinska, JH2
Ballard, C1
Thomas, A1
Gerry, S1
Yu, LM1
Aarsland, D1
Merritt, C1
Corbett, A1
Davison, C1
Sharma, N1
Khan, Z1
Creese, B1
Loughlin, P1
Bannister, C1
Burns, A1
Win, SN1
Walker, Z1
Hwa, LS1
Nathanson, AJ1
Shimamoto, A1
Tayeh, JK1
Wilens, AR1
Holly, EN1
Newman, EL1
DeBold, JF1
Miczek, KA1
Caudron, M1
Rolland, B1
Deheul, S1
Geoffroy, PA1
Thomas, P1
Amad, A1
Marszalek-Grabska, M1
Jenda, M1
Gawel, K1
Kotlinska, J1
Bochenski, M1
Kwak, YT1
Han, IW1
Suk, SH1
Koo, MS1
Idrus, NM1
McGough, NN1
Riley, EP1
Thomas, JD1
Bisaga, A2
Sullivan, MA1
Cheng, WY1
Carpenter, KM1
Mariani, JJ1
Levin, FR1
Raby, WN1
Nunes, EV1
Rehni, AK1
Singh, N1
Rachamalla, M1
Tikoo, K1
Maldonado, C1
Cauli, O1
Rodríguez-Arias, M1
Aguilar, MA1
Miñarro, J1
Sukhotina, IA2
Zvartau, EE2
Danysz, W3
Bespalov, AY2
Zakharova, E1
Malyshkin, A1
Kashkin, V1
Neznanova, O1
Sukhotina, I1
Bespalov, A1
Thuerauf, N1
Lunkenheimer, J1
Lunkenheimer, B1
Sperling, W1
Bleich, S1
Schlabeck, M1
Wiltfang, J1
Kornhuber, J1
Krupitsky, EM1
Rudenko, AA1
Burakov, AM1
Slavina, TY1
Grinenko, AA1
Pittman, B1
Gueorguieva, R1
Petrakis, IL1
Krystal, JH1
Harris, AC1
Rothwell, PE1
Gewirtz, JC1
Popik, P2
Lukoyanov, NV1
Paula-Barbosa, MM1
Comer, SD1
Ward, AS1
Kleber, HD1
Fischman, MW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence[NCT00476242]Phase 2/Phase 382 participants (Actual)Interventional2008-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Opiate Craving Based on Heroin Craving Scale

Range 0- 100 ( 0= no craving; 100= very strong craving (NCT00476242)
Timeframe: Average of twice weekly assessments for 12 weeks of study or length of participation

Interventionunits on a scale (Mean)
Placebo and Vivitrol18.47
Memantine and Vivitrol15.74

Opiate Use Measured by Urine Toxicology Results

Opiate use was qualified by the number of opiate positive urine results. (NCT00476242)
Timeframe: 3x/week during 12 weeks of the trial or study participation

InterventionPercent of total urine samples (Median)
Memantine and Vivitrol9
Placebo and Vivitrol10

Retention in Treatment The Primary Outcome Measure Will be the Dichotomous Measure Retention in Treatment (Whether the Patient Completes the 12 Week Trial, Yes/no).

(NCT00476242)
Timeframe: Week 12

Interventionparticipants (Number)
Memantine and Vivitrol12
Placebo and Vivitrol19

Reviews

2 reviews available for memantine and Drug Withdrawal Symptoms

ArticleYear
Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Journal of substance abuse treatment, 2019, Volume: 107

    Topics: Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Hum

2019
Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review.
    Drug and alcohol dependence, 2020, 03-01, Volume: 208

    Topics: Analgesics, Opioid; Excitatory Amino Acid Antagonists; Humans; Ketamine; Memantine; Methadone; Opiat

2020

Trials

5 trials available for memantine and Drug Withdrawal Symptoms

ArticleYear
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Journal of the American Medical Directors Association, 2015, Volume: 16, Issue:4

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cross-Over Studies; Dose-Response

2015
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
    Drug and alcohol dependence, 2011, Dec-01, Volume: 119, Issue:1-2

    Topics: Adult; Disease Progression; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Medication A

2011
Memantine fails to facilitate partial cigarette deprivation in smokers--no role of Memantine in the treatment of nicotine dependency?
    Journal of neural transmission (Vienna, Austria : 1996), 2007, Volume: 114, Issue:3

    Topics: Adult; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Memantine; Nicotine; Nicotinic Ag

2007
Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.
    Alcoholism, clinical and experimental research, 2007, Volume: 31, Issue:4

    Topics: Adult; Alcoholism; Arousal; Autonomic Nervous System; Depression; Diazepam; Excitatory Amino Acid An

2007
The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.
    Psychopharmacology, 2001, Volume: 157, Issue:1

    Topics: Adult; Dextromethorphan; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Morphin

2001

Other Studies

17 other studies available for memantine and Drug Withdrawal Symptoms

ArticleYear
Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    The American journal on addictions, 2017, Volume: 26, Issue:8

    Topics: Adolescent; Age Factors; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Cognitive Beh

2017
Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway.
    Neuroscience letters, 2018, 11-01, Volume: 686

    Topics: Alcoholism; Animals; Anxiety; Anxiety Disorders; Calcium-Calmodulin-Dependent Protein Kinase Type 2;

2018
The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Aug-01, Volume: 45

    Topics: Acamprosate; Amphetamine; Animals; Anxiety; Bridged Bicyclo Compounds; Dose-Response Relationship, D

2013
Aggression and increased glutamate in the mPFC during withdrawal from intermittent alcohol in outbred mice.
    Psychopharmacology, 2015, Volume: 232, Issue:16

    Topics: Aggression; Animals; Behavior, Animal; Ethanol; Excitatory Amino Acid Antagonists; Glutamic Acid; Ke

2015
Catatonia and cannabis withdrawal: A case report.
    Substance abuse, 2016, Volume: 37, Issue:1

    Topics: Adult; Catatonia; Excitatory Amino Acid Antagonists; Humans; Hypnotics and Sedatives; Lorazepam; Mal

2016
Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats.
    Brain research, 2016, 07-01, Volume: 1642

    Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Antidepressive Agents; Central Nervous System S

2016
The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats.
    European journal of pharmacology, 2008, Nov-19, Volume: 598, Issue:1-3

    Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Behavior, Animal; Central Nervous System Depressa

2008
Two cases of discontinuation syndrome following cessation of memantine.
    Geriatrics & gerontology international, 2009, Volume: 9, Issue:2

    Topics: Aged; Alzheimer Disease; Humans; Male; Memantine; Substance Withdrawal Syndrome; Syndrome; Treatment

2009
Administration of memantine during ethanol withdrawal in neonatal rats: effects on long-term ethanol-induced motor incoordination and cerebellar Purkinje cell loss.
    Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:2

    Topics: Alcohol Drinking; Animals; Animals, Newborn; Ataxia; Cerebellum; Ethanol; Excitatory Amino Acid Anta

2011
Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.
    Naunyn-Schmiedeberg's archives of pharmacology, 2012, Volume: 385, Issue:6

    Topics: Analgesics, Opioid; Animals; Behavior, Animal; Brain; Cysteine Proteinase Inhibitors; Female; Histon

2012
Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal.
    Behavioural brain research, 2003, Sep-15, Volume: 144, Issue:1-2

    Topics: Animals; Behavior, Animal; Conditioning, Psychological; Dizocilpine Maleate; Dose-Response Relations

2003
Caffeine withdrawal syndrome in social interaction test in mice: effects of the NMDA receptor channel blockers, memantine and neramexane.
    Behavioural pharmacology, 2004, Volume: 15, Issue:3

    Topics: Animals; Caffeine; Cyclopentanes; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Mal

2004
The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
    Behavioural pharmacology, 2004, Volume: 15, Issue:4

    Topics: Acamprosate; Animals; Choice Behavior; Ethanol; Male; Memantine; Naloxone; Naltrexone; Narcotic Anta

2004
Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia.
    Psychopharmacology, 2008, Volume: 196, Issue:4

    Topics: Analgesics, Opioid; Animals; Hyperalgesia; Male; Memantine; Morphine; Morphine Dependence; Naloxone;

2008
Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 280, Issue:2

    Topics: Animals; Feeding Behavior; Male; Maze Learning; Memantine; Memory; Morphine; Naloxone; Rats; Rats, W

1997
Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice.
    Psychopharmacology, 2000, Volume: 149, Issue:4

    Topics: Aggression; Animals; Cyclopentanes; Excitatory Amino Acid Antagonists; Male; Memantine; Mice; Morphi

2000
Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol.
    Neuroscience letters, 2001, Aug-17, Volume: 309, Issue:1

    Topics: Alcohol-Induced Disorders, Nervous System; Animals; Brain; Cognition Disorders; Dizocilpine Maleate;

2001
chemdatabank.com